| Identification | Back Directory | [Name]
AR-42 | [CAS]
935881-37-1 | [Synonyms]
AR-42
CS-15
OSU-HD
HDAC-42
OSU-HDAC42
(S)-HDAC 42
NSC-D736012
AR-42 (HDAC-42)
(S)-HDAC-42,AR-42
AR-42 (OSU-HDAC42)
AR-42 (HDAC-42, NSC-736012, OSU-42)
(S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide
N-hydroxy-4-[(3-methyl-1-oxo-2-phenylbutyl)amino]benzamide
(S)-(+)-N-Hydroxy-4-(3-methyl-2-phenyl-butyrylamino)benzamide
(S)-(+)-N-Hydroxy-4-(3-methyl-2-phenyl-butyrylamino)benzamide AR 42
Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-α-(1-methylethyl)-, (αS)- | [EINECS(EC#)]
802-219-4 | [Molecular Formula]
C18H20N2O3 | [MDL Number]
MFCD17676151 | [MOL File]
935881-37-1.mol | [Molecular Weight]
312.363 |
| Chemical Properties | Back Directory | [density ]
1.223 | [storage temp. ]
Inert atmosphere,Store in freezer, under -20°C | [solubility ]
insoluble in EtOH; insoluble in H2O; ≥15.62 mg/mL in DMSO | [form ]
Powder | [pka]
8.94±0.10(Predicted) | [color ]
White to light brown |
| Hazard Information | Back Directory | [Uses]
AR-42 is a broad spectrum deacetylase inhibitor of both histone and non-histone proteins, which has demonstrated greater potency and activity in solid tumors and hematological malignancies. AR-42 is k
nown utilized as a novel, oral cancer therapy currently in early clinical development. | [Definition]
ChEBI: (S)-HDAC-42 is an amidobenzoic acid. | [Biological Activity]
ar-42 (also known as osu-hdac42), a derivative of hydroxamate-tethered phenylbutyrate, is a novel and potent inhibitor of histone deacetylase (hdac) that potently inhibits the activity of hdac with 50% inhibition concentration ic50 value of 16 nm and induces histone h3 acetylation, α-tubulin acetylation and p21 up-regulation, which have been considered as the hallmark indicators of hdac inhibition. ar-42 has been found to modulate several apoptosis inhibitors as well as cell survival regulator, including akt, bcl-xl, bax, ku70 and surviving, and exert potent antitumor activity against multiple tumor types, such as human prostate and hepatic cancers, at least partially through pi3k/akt pathway inhibition.matthew l. bush?, janet oblinger?, victoria brendel, griffin santarelli, jie huang, elena m. akhmametyeva, sarah s. burns, justin wheeler, jeremy davis, charles w. yates, abhik r. chaudhury, samuel kulp, ching-shih chen, long-sheng chang, d. bradley welling, and abraham jacob. ar42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. neuro-oncology 13(9):983–999, 2011aaron m. sargeant, robert c. rengel, samuel k. kulp, et al. osu-hdac42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model cancer res 2008;68:3999-4009.qiang lu, da-sheng wang, chang-shi chen, yuan-dong hu, and ching-shih chen. structure-based optimization of phenylbutyrate-derived histone deacetylaseinhibitors. j. med. chem. 2005, 48, 5530-5535 | [target]
HDAC |
|
| Company Name: |
T&W GROUP
|
| Tel: |
021-61551611 13296011611 |
| Website: |
www.trustwe.com/ |
|